Fibrinogen: A predictor of vascular disease

Current Pharmaceutical Design

Volumn 13, Issue 16, 2007, Pages 1647-1659

  Kakafika, A I ^a   Liberopoulos, E N ^a   Mikhailidis, D P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antihypertensive drugs; Atherogenesis; CVD; Fibrinogen; Lipid lowering drugs; Metabolic syndrome; Platelets; Smoking; Thrombosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CIPROFIBRATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; METOPROLOL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; PRAZOSIN; RESIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL;

AGE; ALCOHOL CONSUMPTION; ARTERY DISEASE; ATHEROGENESIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG USE; ENVIRONMENTAL FACTOR; EXERCISE; FIBRINOGEN BLOOD LEVEL; GENDER; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INFECTION; ISCHEMIC HEART DISEASE; META ANALYSIS; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; NUTRITION; PATHOPHYSIOLOGY; PLASMA VISCOSITY; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RACE; REVIEW; RISK ASSESSMENT; SMOKING; SOCIAL ASPECT; STROKE; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION;

EID: 34250851882     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780831310     Document Type: Review

References (252)

1. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
2. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and MI. N Engl J Med 1984; 311: 501-5.
3. Doolittle RF, Spraggon G, Everse SJ. Three-dimensional structural studies on fragments of fibrinogen and fibrin. Curr Opin Struct Biol 1998; 8: 792-8.
4. Herrick S, Blanc-Brude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol 1999; 31: 741-6.
5. Naito M, Funaki C, Hayashi T, Yamada K, Asai K, Yoshimine N, Kuzuya F. Substrate-bound fibrinogen, fibrin and other cell attachement-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis 1992; 96: 227-34.
6. Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15: 355-70.
7. Cahill M, Mistry R, Barnett DB. The human platelet fibrinogen receptor: clinical and therapeutic significance. Br J Clin Pharmacol 1992; 33: 3-9.
8. Schneider DJ, Taatjes DJ, Howard DB, Sobel BE. Increased reactivity of platelets induced by fibrinogen independent of its binding to the IIb-IIIa surface glycoprotein: A potential contributor to cardiovascular risk. J Am Coll Cardiol 1999; 33: 261-6.
9. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease. J Clin Pathol 1985; 38: 1166-71.
10. Van de Stolpe A, Jacobs N, Hage WJ, Tertoolen L, Van Kooyk Y, Novakova IR, et al. Fibrinogen binding to ICAM-1 on EA.hy 926 endothelial cells is dependent on an intact cytoskeleton. Thromb Haemost 1996; 75: 182-9.
11. Forsyth CB, Solovjov DA, Ugarova TP, Plow EF. Integrin alpha (M)beta (2)-mediated cell migration to fibrinogen and its recognition peptides. J Exp Med 2001; 193: 1123-33.
12. Kant JA, Fornace AJ Jr, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 1985; 82: 2344-8.
13. Yu S, Sher B, Kudryk B, Redman CM. Fibrinogen precursors. Order of assembly of fibrinogen chains. J Biol Chem 1984; 259: 10574-81.
14. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al. β-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM Study Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93: 440-9.
15. Van't Hooft FM, von Bahr SJF, Silveira A, Iliadou A, Eriksson P, Hamsten A. Two common, functional polymorphisms in the promoter region of the β-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol 1999; 19: 3063-70.
16. Schmidt H, Schmidt R, Niederkorn K, Horner S, Becsagh P, Reinhart B, et al. β-fibrinogen gene polymorphism (C148→T) is associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 487-92.
17. Soria JM, Almasy L, Souto JC, Buil A, Lathrop M, Blangero J, et al. A genome search for genetic determinants that influence plasma fibrinogen levels. Arterioscler Thromb Vasc Biol 2005; 25: 1287-92.
18. Krobot K, Hense HW, Cremer P, Eberle E, Keil U. Determinants of plasma fibrinogen: Relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990. Arterioscler Thromb 1992; 12: 780-8.
19. Laharrague PF, Cambus JP, Fillola G, Corberand JX. Plasma fibrinogen and physiological aging. Aging (Milano) 1993; 5: 445-9.
20. Prisco D, Fedi S, Brunelli T, Cellai AP, Hagi MI, Gianni R, et al. Fibrinogen and factor VIIag in healthy adolescents: The Floren-teen (Florence teenager) Study. Thromb Haemost 1996; 75: 778-81.
21. Tarallo P, Henny J, Gueguen R, Siest G. Reference limits of plasma fibrinogen. Eur J Clin Chem Clin Biochem 1992; 30: 745-51.
22. Wattanakit K, Folsom A, Chambless L, Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2005; 149: 606-12.
23. Ishikawa S, Kario K, Nago N, Kayaba K, Hiraoka J, Matsuo H, et al. Factor VII and fibrinogen levels examined by age, sex, and other atherosclerotic risk factors in a Japanese population. The Jichi Medical School Cohort Study. Thromb Haemost 1997; 77: 890-3.
24. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
25. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience. Am Heart J 1990; 120: 672-6.
26. Sinha S, Luben RN, Welch A, Bingham S, Wareham NJ, Day NE, et al. Fibrinogen and cigarette smoking in men and women in the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population. Eur J Cardiovasc Prev Rehabil 2005; 12: 144-50.
27. McCarty MF. Inteleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: Down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses 1999; 52: 465-77.
28. McCallum PK. Markers of hemostasis and systemic inflammation in heart disease and atherosclerosis in smokers. Proc Am Thorac Soc 2005; 2: 34-43.
29. Mennen LI, Balkau B, Vol S, Caces E, Eschwege E. Fibrinogen: A possible link between alcohol consumption and cardiovascular disease? DESIR Study Group. Arterioscler Thromb Vasc Biol 1999; 19: 887-92.
30. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: Results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J 2004; 25: 2092-100.
31. Tarallo P, Henny J, Gueguen R, Siest G. Reference limits of plasma fibrinogen. Eur J Clin Chem Clin Biochem 1992; 30: 745-51.
32. Schroder H, Ferrandez O, Jimenez Conde J, Sanchez-Font A, Marrugat J. Cardiovascular risk profile and type of alcohol beverage consumption: A population-based study. Ann Nutr Metab 2005; 49: 100-6.
33. Hansen AS, Marckmann P, Dragsted LO, Finne Nielsen IL, Nielsen SE, Gronbaek M. Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease. Eur J Clin Nutr 2005; 59: 449-55.
34. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-9.
35. Doulalas AD, Rallidis LS, Gialernios T, Moschonas DN, Kougioulis MN, Rizos I, et al. Association of depressive symptoms with coagulation factors in young healthy individuals. Atherosclerosis 2006; 186: 121-5.
36. Brunner E, Davey Smith G, Marmot M, Canner R, Beksinska M, O'Brien J. Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen. Lancet 1996; 347: 1008-13.
37. Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34: 1435-9.
38. Zito F, Di Castelnuovo A, D'Orazio A, Negrini R, De Lucia D, Donati MB, et al. Helicobacter pylori infection and the risk of myocardial infarction: Role of fibrinogen and its genetic control. Thromb Haemost 1999; 82: 14-8.
39. Cook PJ, Lip GY, Davies P, Beevers DG, Wise R, Honeybourne D. Chlamydia pneumoniae antibodies in severe essential hypertension. Hypertension 1998; 31: 589-94.
40. Peach HG, Bath NE, Farish SJ. Helicobacter pylori infection is not a correlate of plasma fibrinogen in the Australian population. Clin Lab Haematol 1999; 21: 41-3.
41. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-23.
42. Danesh J, Whincup P, Lewington S, Walker M, Lennon L, Thomson A, et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 2002; 23: 371-5.
43. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-97.
44. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
45. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283-96.
46. Mertens I, Van Gaal LF. Obesity, heamostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
47. Rillaerts E, Van Gaal L, Xiang DZ, Vansant G, De Leeuw I. Blood viscosity in human obesity: Relation to glucose tolerance and insulin status. Int J Obes 1989; 13: 7139-45.
48. Avellone G, Di Garbo V, Cordova R, Cucinella G, De Simone R, Raneli G, et al. Evaluation of cardiovascular risk factors in overweight and obese subjects. Int Angiol 1994; 13: 25-9.
49. Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 10: 1044-8.
50. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution. Thromb Res 1994; 75: 223-31.
51. Ditschuneit HH, Flechtner-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res 1995; 3: 43-8.
52. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: A model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280: E827-47.
53. Fanari P, Somazzi R, Nasrawi F, Ticozzelli P, Grugni G, Agosti R, et al. Haemorheological changes in obese adolescents after short-term diet. Int J Obes 1993; 17: 487-94.
54. Primrose JN, Davies JA, Prentice CRM, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-9.
55. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-33.
56. Juhan Vague I, Thompson SG, Jespersen J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-73.
57. Raynaud E, Perez-Martin A, Brun J, Alissa-Benhaddad A, Fedou C, Mercier J. Ralationships between fibrinogen and insulin resistance. Atherosclerosis 2000; 150: 365-70.
58. Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562-8.
59. Coban E, Sari R, Ozdogan M, Akcit F. Levels of plasma fibrinogen and d-dimer in patients with impaired fasting glucose. Exp Clin Endocrinol Diabetes 2005; 113: 35-7.
60. Muntner P, He J, Chen J, Fonseca V, Whelton P. Prevalence of non-traditional cardiovascular disease risk factors with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686-95.
61. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a commom antecedent? Diabetes Care 1999; 22(Supp l3): C25-30.
62. Bogar L. Hemorheology and hypertension: Not "chicken or egg" but two chickens from similar eggs. Clin Hemorheol Microcirc 2002; 26:81-3.
63. Kannel WB. Influence of multiple risk factors on the hazard of hypertension. J Cardiovasc Pharmacol 1990; 16(Suppl 5): S53-7.
64. Spencer CG, Gurney D, Felmeden DC, Blann AD, Beevers DG, Lip GY. Platelet and haemorhelogical markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Intern Med 2004; 255: 59-67.
65. Marques-Vidal P, Cambou JP, Bongard V, Ruidavets JB, Ferrieres J. Systolic and diastolic hypertension: No relationship with lipid and inflammatory markers in Haute-Garonne, France. Am J Hypertens 2003; 16: 681-4.
66. Arikan E, Sen S. Endothelial damage and hemostatic markers in patients with uncomplicated mild-to-moderate hypertension and relationship with risk factors. Clin Appl Thromb Hemost 2005; 11: 147-59.
67. Makris T, Stavroulakis G, Hatzizacharias A, Krepsi P, Margos P, Tsoukala C, et al. Parental history of hypertension is associated with coagulation-fibrinolytic balance disorders. Thromb Res 2003; 111: 45-9.
68. Contreras T, Vaya A, Palanca S, Sola E, Corella D, Aznar J. Influence of plasmatic lipids on the hemorheological profile in healthy adults. Clin Hemorheol Microcirc 2004; 30: 423-5.
69. Hiraga T, Shimada M, Tsukada T, Murase T. Hypertriglyceridemia, but not hypercholesterolemia is associated with the alterations of the fibrinolytic system. Horm Metab Res 1996; 28:603-6.
70. Meyer M, Schreck R, Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-kB and AP-1 in intact cells: AP-1 as secondary factor antioxidant-responsive factor. Eur Mol Biol Org J 1993; 12: 2005-15.
71. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling. Curr Med Res Opin 2001; 16: 269-75.
72. Archer SL, Green D, Chamberlain M, Dyer AR, Liu K. Association of dietary fish and n-3 fatty acid intake with hemostatic factors in the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol 1998; 18: 1119-23.
73. El-Sayed MS, Jones PG, Sale C. Exercise induces a change in plasma fibrinogen concentration: Fact or fiction? Thromb Res 1999; 96: 467-72.
74. Li-Saw-Hee FL, Blann AD, Edmunds E, Gibbs CR, Lip GYH. Effect of acute exercise on the raised plasma fibrinogen, soluble P-salectin and vWF levels in Chronic Atrial Fibrillation. Clin Cardiol 2001; 24: 409-14.
75. Gibbs CR, Blann AD, Edmunds E, Watson RDS, Lip GYH. Effects of acute exercise on hemorrheological, endothelial,and platelet markers in patients with chronic heart failure in sinus rhythm. Clin Cardiol 2001; 24: 724-9.
76. Connelly JB, Cooper JA, Meade TW. Strenuous exercise, plasma fibrinogen, and factor VII activity. Br Heart J 1992; 67: 351-4.
77. Elwood PC, Yarnell JW, Pickering J, Fehily AM, O'Brien JR. Exercise, fibrinogen, and other risk factors for ischaemic heart disease. Caerphilly Prospective Heart Disease Study. Br Heart J 1993; 69: 183-7.
78. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol 2004; 44: 152-8.
79. Mezzano D. Distinctive effects of red wine and diet on haemostatic cardiovascular risk factors. Biol Res 2004; 37: 217-24.
80. Gaudard A, Varlet-Marie E, Bressolle F, Mercier J, Brun JF. Nutrition as a determinant of blood rheology and fibrinogen in athletes. Clin Hemorheol Microcirc 2004; 30: 1-8.
81. Lee AJ, Lowe GD, Smith WC, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993; 83: 616-21.
82. Pripp U, Eriksson-Berg M, Orth-Gomer K, Schenck-Gustafsson K, Landgren BM. Does body mass index, smoking, lipoprotein levels, surgically induced menopause, hormone replacement therapy, years since menopause, or age affect hemostasis in postmenopausal women? Gend Med 2005; 2: 88-95.
83. Sowers MR, Matthews KA, Jannausch M, Randolph JF, McConnell D, Sutton-Tyrrell K, et al. Hemostatic factors and estrogen during the menopausal transition. J Clin Endocrinol Metab 2005; 90: 5942-8
84. Szymanski LM, Kessler CM, Fernhall B. Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women. J Appl Physiol 2005; 98: 1341-8.
85. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormone-replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77: 945-51.
86. Osmanagaoglu MA, Osmanagaoglu S, Osmanagaoglu T, Okumus B, Bozkaya H. Effect of different preparations of hormone therapy on lipid and glucose metabolism, coagulation factors, and bone mineral density in overweight and obese postmenopausal women. Fertil Steril 2005; 84: 384-93.
87. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-44.
88. Balleisen L, Schulte H, Assmann G, Van De Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; 1: 461.
89. Assmann G, Cullen P, Heinrich J, Schulte H. Hemostatic variables in the prediction of coronary risk: Results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996; 32: 364-70.
90. Cremer P, Nagel D, Bottcher B, Seidel D. Fibrinogen: Ein koronarer Risikofaktor. Diagnose Labor 1992; 42: 28-35.
91. Marchioli R, Avanzini F, Barzi F, Chieffo C, Di Castelnuovo A, Franzosi MG, et al.; GISSI-Prevenzione Investigators. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J 2001; 22: 2085-103.
92. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
93. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: An update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-77.
94. Davey Smith G, Harbord R, Milton J, Ebrahim S, Sterne JA. Does elevated plasma fibrinogen increase the risk of coronary heart disease? Arterioscler Thromb Vasc Biol 2005 E-Pub.
95. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA 2005; 294: 1799-809.
96. Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, et al. Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 1989; 77: 209-13.
97. Umemoto S, Suzuki N, Fujii K, Fujii A, Fujii T, Iwami T, et al. Eosinophil counts and plasma fibrinogen in patients with vasospastic angina pectoris. Am J Cardiol 2000; 85: 715-9.
98. Leschke M, Blanke H, Stellwaag M, Motz W, Strauer BE. Hyperfibrinogenemia and pathological plasma viscosity. Pathogenetic factors in unstable angina pectoris? Dtsch Med Wochenschr 1988; 113: 1175-81.
99. Held C, Hjemdahl P, Hakan Wallen N, Bjorkander I, Forslund L. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis 2000; 148: 179-88.
100. van der Bom JG, de Maat MP, Bots ML, Haverkate F, de Jong PT, Hofman A, et al. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 1998; 18: 621-5
101. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, et al. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998; 80: 749-56.
102. Eriksson M, Egberg N, Wamala S, Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K. Relationship between plasma fibrinogen and coronary heart disease in women. Arterioscler Thromb Vasc Biol 1999; 19: 67-72.
103. Martin JF, Bath PM, Burr ML. Mean platelet volume and myocardial infarction. Lancet 1992; 338: 1409-11.
104. Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost 1995; 73: 374-9.
105. Schmitz-Huebner U, Thompson SG, Balleisen L, Fechtrup C, Grosse-Heitmeyer W. Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis. Br Heart J 1988; 59: 287-91.
106. Panagiotakos DB, Pitsavos C, Skoumas J, Chrysohoou C, Toutouza M, Stefanadis CI, et al. Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: A 15-year follow-up (1987-2002). Curr Med Res Opin 2003; 19: 89-94.
107. Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N. Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis 2002; 164: 371-8.
108. Germing A, von Dryander S, Machraoui A, Bojara W, Lawo T, Grewe P, et al. Hyperfibrinogenemia increases the risk of cardiac events after coronary artery stenting. Heart Vessels 2000;15: 263-7.
109. Avci A, Boyaci A, Cagli K, Cosgun A, Gokce V, Duru E, et al. Influence of haematological parameters before coronary angioplasty on subsequent restenosis. Acta Cardiol 2004; 59: 263-8.
110. Meckel CR, Anderson TJ, Mudge GH, Mitchell RN, Yeung AC, Selwyn AP, et al. Hemostatic/fibrinolytic predictors of allograft coronary artery disease after cardiac transplantation. Vasc Med 1997; 2: 306-12.
111. Tribouilloy C, Peltier M, Colas L, Senni M, Ganry O, Rey JL, et al. Fibrinogen is an independent marker for thoracic aortic atherosclerosis. Am J Cardiol 1998; 81: 321-6.
112. Ernst E, Matrai A, Marshall M. Blood rheology in patients with transient ischemic attacks. Stroke 1988; 19: 634-6.
113. Coull BM, Beamer N, de Garmo P, Sexton G, North F, Knox R, et al. Chronic hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke 1991; 22: 162-8.
114. Resch KL, Ernst E, Matrai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992; 117: 371-5.
115. Grotta JC, Yatsu TM, Pettigrew LC, Rhoades H, Bratina P, Vital D, et al. Prediction of carotid stenosis progression by lipid and heamatologic measurements. Neurology 1989; 39: 1325-31.
116. Woodward M, Lowe GD, Campbell DJ, Colman S, Rumley A, Chalmers J, et al. Associations of inflammatory and hemostatic variables with he risk of recurrent stroke. Stroke 2005; 36: 2143-7.
117. Rothwell PM, Howard SC, Power DA, Gutnikov SA, Algra A, van Gijn J, et al. Fibrinogen concentration and risk of ischemic stroke and acute coronary events in 5113 patients with transient ischemic attack and minor ischemic stroke. Stroke 2004; 35: 2300-05.
118. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001; 32: 133.
119. Milionis HJ, Liberopoulos E, Goudevenos J, Bairaktari ET, Seferiadis K, Elisaf MS. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol 2005; 99: 269-75.
120. Kristensen B, Malm J, Nilsson T, Hutdin J, Carlberg B, Olsson T. Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke 1998; 29: 2261-7.
121. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-43.
122. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995; 15: 1263-8.
123. Leng GC, Papacosta O, Whincup P, Wannamethee G, Walker M, Ebrahim S, et al. Femoral atherosclerosis in an older British population: prevalence and risk factors. Atherosclerosis 2000; 152: 167-74.
124. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143: 961-5.
125. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, et al. D-dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation 2003; 107: 3191-8.
126. Cheshire NJ, Wolfe JH, Barradas MA, Chambler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996; 11: 479-86.
127. Wiseman S, Powell J, Greenhalgh R, McCollum C, Kenchington G, Alexander C, et al. The influence of smoking and plasma factors on prosthetic graft patency. Eur J Vasc Surg 1990; 4: 57-61.
128. Wiseman S, Kenchington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM, et al. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ 1989; 299: 643-6.
129. Lee AJ, Fowkes FG, Lowe GD, Connor JM, Rumley A. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost 1999; 81: 553-60.
130. Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL, et al. Risk factors for peripheral arterial disease incidence in persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2005; 180: 389-97.
131. Tkac I, Molcanyiova A. Fibrinogen and albuminuria are related to the presence and severity of peripheral arterial disease in women with type 2 diabetes mellitus. Angiology 1997; 48: 715-9.
132. Sullivan ME, Miller MA, Bell CR, Jagroop IA, Thompson CS, Khan MA, et al. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study. Int Angiol 2001;20: 195-9.
133. Shabbir M, Mikhailidis DP, Morgan RJ. Erectile dysfunction: An underdiagnosed condition associated with multiple risk factors. Curr Med Res Opin 2004; 20: 603-6.
134. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17.
135. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
136. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med 2003; 139: 670-82.
137. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2425-43.
138. Undas A, Brummel-Ziedins KE, Mann KG. Satins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-94.
139. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 2000; 76: 23-32.
140. Isaacsohn JL, Setaro JF, Nicholas C, Davey JA, Diotalevi LJ, Christianson DS, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74:735-7.
141. Koenig W, Hehr R, Ditschuneit HH, Kuhn K, Ernst E, Rosenthal J, et al. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)? J Clin Pharmacol. 1992; 32: 539-45.
142. Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 1990; 83: 53-8.
143. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1475-81.
144. Mayer J, Eller T, Brauer P, Solleder EM, Schäfer RM, Keller F, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196-201.
145. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, et al. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 1999; 33: 1294-304.
146. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3.
147. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-33.
148. Wada H, Mori Y, Kaneko T, Wakita Y, Nakase T, Minamikawa K, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112-6.
149. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 553-8.
150. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani GD. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res 1994; 55; 1335-44.
151. Dupuis J, Tardif JC, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-33.
152. Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli G, Avellone G. Non lipid, dose dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur J Clin Pharmacol 2000; 56: 277-84.
153. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
154. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004; 148: 635-640.
155. Jerling JC, Vorster HH, Oosthuizen W, Vermaak WJH. Effect of simvastatin, a 3-hydroxy-3methylglutaryl Coenzyme-A reductase inhibitor, on the haemostatic balance of familial hypercholesterolaemic subjects. Fibrinol Proteol 1997; 11: 91-6.
156. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005; 21: 231-43.
157. Rizos E, Miltiadous G, Elisaf M. The effect of fluvastatin on plasma fibrinogen levels. Curr Med Res Opin 2002; 3: 154-5.
158. Cortellaro M, Confrancesco E, Boschetii C, Cortellaro F, Mancini M, Mariani M, et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C- reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Thromb Haemost 2000; 83: 549-53
159. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001; 155: 463-6
160. Lin TH, Huang CH, Voon WC, Yen HW, Lai HM, Liang HY, et al. The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia. Kaohsiung J Med Sci 2000; 16: 600-6.
161. Gottsäter A, Anwaar I, Lind P, Mattiasson I, Lindgarde F. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coag Fibrinolysis 1999; 10: 133-40.
162. Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999; 40: 265-71.
163. Nair DR, Papadakis JA, Jagroop IA Mikhailidis DP, Winder AF. Statins and fibrinogen. Lancet 1998; 351: 1430.
164. Wierzbicki AS, Lumb PJ, Chik G, Crook MA. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol 2001; 87: 338-40.
165. Athyros VG, Papageorgiou AA, Hatzikonstantinou HA, Athyrou VV, Kontopoulos AG. Effect of atorvastatin versus simvastatin on lipid profile and plasma fibrinogen in patients with hypercholesterolaemia. Clin Drug Invest 1998; 16: 219-27.
166. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia-a pilot study involving serial sampling. Curr Med Res Opin 2001; 16: 269-75.
167. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999; 6: 113-6.
168. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: Evidence for antiinflammatory effects of rosuvastatin. Circulation 2003; 108: 1368-74.
169. Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-54.
170. Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988; 71: 113-9.
171. Mikhailidis DP, Winder AF. A place for fibrinogen-lowering drugs in cardiovascular disease? J Drug Develop Clin Pract 1995; 7: 61-70.
172. Maison P, Mennen L, Sapinho D, Balkau B, Sigalas J, Chesnier MC, et al. D.E.S.I.R. Study Group. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 2002; 160: 155-60.
173. Stringer MD, Steadman CA, Kakkar VV. Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: Some undiscovered actions. Curr Med Res Opin 1990; 12: 207-14.
174. Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 1999; 93: 2991-8.
175. Almer RO, Kjellstrom T. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 1986; 61: 81-5.
176. Mathur S, Barradas MA, Mikhailidis DP, Dandona P. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: A pilot study. Diab Res 1990; 14: 133-8.
177. Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, et al. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Clin Invest 1992; 43: 219-23.
178. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-7.
179. Behar S for the BIP Study Group. Lowering fibrinogen levels: Clinical update. Blood Coagul Fibrinol 1999; 10(Suppl 1): S41-3.
180. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: Randomised controlled trial. Br Med J 2002; 325: 1139-43.
181. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
182. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: Response to ciprofibrate or lifestyle advice. Int Angiol 1998; 17: 225-33.
183. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002; 7: 219-26.
184. Rizos E, Kostoula A, Elisaf M, Mikhailidis DP. Effect of ciprofibrate on C-reactive protein and fibrinogen levels. Angiology 2002; 53: 273-7
185. Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, et al. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: A comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metabolism 2005; 54: 677-81.
186. Kon Koh A, Yeal Ahn J, Hwan Han S, Kyu Jin D, Sik Kim H, Cheon Lee K, et al. Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 2004; 174: 379-83.
187. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004; 9: 27-33.
188. Yesilbursa D, Serdar A, Saltan Y, Serdar Z, Heper Y, Guclu S, et al. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol 2005; 62: 526-30.
189. Bairaktari ET, Tzallas CS, Tsimihodimos VK, Liberopoulos EN, Miltiadous GA, Elisaf MS. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999; 6: 113-6.
190. Achimastos A, Liberopoulos E, Nikas S, Bairaktari E, Miltiadous G, Tsimihodimos V, et al. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin. 2002; 18: 59-63.
191. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, Hamilton G, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: Position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69.
192. Kruger B. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia. Int J Clin Pharmacol Res 1994; 14: 177-83.
193. Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolaemia: Effects of treatment. Atherosclerosis 1990; 85: 249-56.
194. Philipp CS, Cisar LA, Saidi P, Kostis JB. Effect of niacin supplementation on fibrinogen levels in patients with peripheral vascular disease. Am J Cardiol 1998; 82: 697-9.
195. Chesney CM, Elam MB, Herd JA, Davis KB, Garg R, Hunninghake D, et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000; 140: 631-6.
196. Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels 1658 Current Pharmaceutical Design, 2007, Vol. 13, No. 16 Kakafika et al. of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160: 1177-84
197. Colussi GL, Baroselli S, Sechi L. ω-3 polyunsaturated fatty acids decrease plasma lipoprotein (a) levels in hypertensive patients. Clin Nutr 2004; 23: 1246-7.
198. Vanschoonbeek K, Feijge MA, Paquay M, Rosing J, Saris W, Kluft C, et al. Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen levels and thrombin generation. Arterioscler Thromb Vasc Biol 2004; 24: 1734-40.
199. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999; 12: 673-81.
200. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemostas 2005; 11: 139-46.
201. Johansson J, Egberg N, Johnsson H, Carlson LA. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb 1993; 13: 1441-8.
202. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2445-64.
203. Fogari R, Zoppi A, Lazzari P, Preti P, Mugellini A, Corradi L, et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-20.
204. Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: Effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-51.
205. Bhatia J, Mahajan P, Sikka M, Kalra OP. Effect of various antihypertensive drugs on plasma fibrinogen levels in patients with essential hypertension. Indian J Med Sci 2001; 55: 491-4.
206. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995; 39: 471-6.
207. Tsagadopoulos D, Antonakoudis H, Makris T, Votteas V, Vyssoulis G, Manolis A, et al. Effect of antihypertensive treatment on lipids and fibrinogen: Greek multicentre study of cilazapril. Cardiology 1996; 87: 524-8.
208. Jagroop IA, Papadakis JA, Mikhailidis DP. Effects of the angiotensin-converting enzyme inhibitor perindropil on endothelial and platelet function in essential hypertension. Platelets 1998; 9: 395-6
209. Pahor M, Franse LV, Deitcher SR, Cushman WC, Johnson KC, Shorr RI, et al. Fosinopril versus amlodipine comparative treatments study: A randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105: 457-61.
210. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: A pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-6.
211. Rosenson RS, Hafner JM. Rheological changes in hypertensive patients treated with ramipril. Clin Hemorheol Microcirc 1997; 17: 41-6.
212. Remkova A, Kratochvilova H. Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension. Blood Coagul Fibrinolysis 2000; 11: 641-4.
213. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316-20.
214. Ekholm M, Wallen NH, Johnsson H, Eliasson K, Kahan T. Long-term angiotensin- converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. Clin Sci (Lond) 2002; 103: 151-5.
215. Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, et al. Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis 2004; 14: 259-69.
216. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783-8.
217. Oubina MP, de Las Heras N, Vazquez-Perez S, Cediel E, Sanz-Rosa D, Ruilope LM, et al. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens 2002; 20: 303-10
218. Makris TK, Stavroulakis G, Papadopoulos DP, Krespi P, Hatzizacharias A, Zilidis A, et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: A comparative study to losartan. Drugs Exp Clin Res 2004; 30: 125-32.
219. Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cradiovasc Pharmacol 1999; 34: 60-3.
220. Liedtke CM, Furin J, Ernsberger P. Alpha 2-adrenergic, but not imidazole, agonists activate NaCl cotransport in rabbit tracheal epithelial cells. Am J Physiol 1993; 263: C568-76.
221. Muravyov AV, Meiselman HJ, Yakusevich VV, Zamishlayev AV. Effects of antihypertensive therapy on hemorheological profiles in female hypertensive patients with initially low or high whole blood viscosity. Clin Hemorheol Microcirc 2002; 26: 125-35.
222. Ding YA, Chou TC, Lin KC. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension. J Hum Hypertens 1994; 8: 273-8.
223. Feher MD, Henderson AD, Wadsworth J, Poulter C, Gelding S, Richmond W, et al. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension-results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. J Hum Hypertens 1990; 4: 571-7.
224. Caimi G, Catania A, Frazzetta F, Capobianco D, Sarno A. Essential hypertension. The behaviour of the haemorheological determinants and their trends during beta-blocker treatment. Jpn Heart J 1983; 24: 723-9.
225. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: A pilot study. J Cardiovasc Pharmacol Ther 2003; 8: 127-34.
226. Linde T, Sandhagen B, Hagg A, Morlin C, Danielson BG. Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: Results of a cross-over study. J Hum Hypertens 1996; 10: 199-205.
227. Taylor SH. Celiprolol in hypertension. Am Heart J 1988; 116: 1426-34.
228. Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV, et al. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: Effects of smoking. Am J Hypertens 2004; 17: 582-9.
229. Waller DG, Challenor VF, Francis DA, Roath OS. Clinical and rheological effects of nifedipine in Raynaud's phenomenon. Br J Clin Pharmacol 1986; 22: 449-54.
230. Koenig W, Sund M, Ernst E, Hehr R, Binner L, Rosenthal J, et al. Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension-a randomized, double-blind, crossover study. J Intern Med 1991; 229: 533-8.
231. Yamauchi K, Furui H, Taniguchi N, Sotobata I. Effects of diltiazem hydrochloride on cardiovascular response, platelet aggregation and coagulating activity during exercise testing in systemic hypertension. Am J Cardiol 1986; 57: 609-12.
232. Slonim A, Paran E, Cristal N. Effect of isradipine on factors affecting blood viscosity. Am J Hypertens 1991; 4: S172-4.
233. Westheim A, Daae LN, Kierulf P, Brusletto B, Holme I, Syvertsen JO. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: Haemodynamic and metabolic effects. J Hypertens 1990; 8(Suppl): S41-6.
234. Toth K, Nemes J, Czopf L, Kapronczay P, Kesmarky G, Juricskay I. Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension. Clin Hemorheol Microcirc 1999; 20: 57-61.
235. Toth K, Kesmarky G, Vekasi J, Nemes J, Czopf L, Kapronczay P, et al. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment. Clin Hemorheol Microcirc 1999; 21: 209-16.
236. Benowitz NL, Fitzgerald GA, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: Comparison of transdermal nicotine and cigarette smoking. J Am Coll Cardiol 1993; 22: 1159-67
237. Netscher DT, Wigoda P, Thornby J, Yip B, Rappaport NH. The hemodynamic and hematologic effects of cigarette smoking versus a nicotine patch. Plast Reconstr Surg 1995; 96: 681-8.
238. Izaguirre-Avila R, De la Pena-Diaz A, Barinagarrementeria-Aldatz F, Gonzalez-Pacheco H, Ramirez-Gutierrez AE, Ruiz-Sandoval JL, et al. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002; 8: 169-77.
239. Jagroop IA, Malley M, Mikhailidis DP. Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002; 8: 381-2.
240. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM; CADET Study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004; 2: 1934-40.
241. Gin H, Roudaut MF, Vergnot V, Baillet L, Rigalleau V. Effect of metformin on fibrinolytic parameters in insulin-treated, type 2 diabetic patients. Diabetes Metab 2003; 29: 505-8.
242. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al; Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-72.
243. Fanghanel G, Silva U, Sanchez-Reyes L, Sisson D, Sotres D, Torres EM. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes. Rev Invest Clin 1998; 50: 389-94.
244. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-9.
245. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-63.
246. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005; 69: 5-13.
247. Fonseca VA, Reynolds T, Hemphill D, Randolph C, Wall J, Valiquet TR, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complicat 1998; 12: 181-6.
248. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlopipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
249. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
250. Kalantzi KJ, Milionis HJ, Mikhailidis DP, Goudevenos JA. Lipid lowering therapy in the elderly: Is there a benefit? Curr Pharm Des 2006; 12(30): 3945-60.
251. Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Des 2005; 11(17): 2199-208.
252. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005; 11(18): 2331-65.